Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Proteomic Prediction of Clinical Benefit in HNSCC
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.
研究概览
详细说明
OBJECTIVES:
- To identify head and neck squamous cell cancer patients who will benefit from treatment with the EGFR inhibitors (i.e., erlotinib hydrochloride, gefitinib, and cetuximab) and VEGF inhibitor (i.e., bevacizumab), based on predictive proteomic profiles in patient blood samples.
OUTLINE: This is a multicenter study.
Blood samples are analyzed for proteomic profile to determine good and bad prognoses in patients treated with or without EGFR inhibitors and/or a VEGF inhibitor.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Tennessee
-
Nashville、Tennessee、美国、37232-6838
- Vanderbilt-Ingram Cancer Center
-
Nashville、Tennessee、美国、37064
- Vanderbilt-Ingram Cancer Center - Cool Springs
-
Nashville、Tennessee、美国、37064
- Vanderbilt-Ingram Cancer Center at Franklin
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
DISEASE CHARACTERISTICS:
Diagnosis of squamous cell head and neck cancer
- Recurrent and/or metastatic disease
Meets 1 of the following criteria:
Previously treated with EGFR inhibitors and/or VEGF inhibitor on 1 of the following clinical trials, and has available blood samples:
- A Phase I/II Study of Bevacizumab (rhu MAb VEGF) in Combination With OSI-774 for Patients With Recurrent or Metastatic Cancer of the Head and Neck
- A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
- Previously treated with cetuximab and has blood samples available from protocol VU-VICC-HN-0356
- Previously treated with conventional chemotherapy and has blood samples available from protocol VU-VICC-HN-0356
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
patients treated with EGFR inhibitors and/or VEGF inhibitor
|
blood samples analysis
|
NOT treated with EGFR inhibitors and/or VEGF inhibitor
|
blood samples analysis
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
大体时间:upon analysis of each patient tissue collection
|
upon analysis of each patient tissue collection
|
合作者和调查者
调查人员
- 学习椅:Barbara Murphy, MD、Vanderbilt-Ingram Cancer Center
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- VICC HN 0744
- P30CA068485 (美国 NIH 拨款/合同)
- VU-VICC-HN-0744
- VU-VICC-070359
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.